Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yige Bao

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
European Urology Oncology|October 17, 2025
Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing StrategyJianjun Ye, Zeyu Chen, Xinyang Liao, et al.
Urologic Oncology|August 10, 2023
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomyJiwei Huang, Ruopeng Su, Cuijian Zhang, et al.
Cancer Medicine|March 23, 2023
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world studyRuopeng Su, Zeyu Chen, Daoping Hong, et al.
Chinese Medical Journal|June 30, 2023
Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in a mice model of orthotopic bladder cancerShi Qiu, Yaqi Qiu, Linghui Deng, et al.
Journal for Immunotherapy of Cancer|September 15, 2025
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironmentInbar A Habaz, Xuejin Ou, Nicole I Wang, et al.
Cancer Medicine|September 16, 2024
Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective studyRuopeng Su, Tingxuan Huang, Liangyou Gu, et al.
Current Opinion in Urology|October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panelsBenjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
European Urology Oncology|October 17, 2025
Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing StrategyJianjun Ye, Zeyu Chen, Xinyang Liao, et al.
Urologic Oncology|August 10, 2023
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomyJiwei Huang, Ruopeng Su, Cuijian Zhang, et al.
Cancer Medicine|March 23, 2023
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world studyRuopeng Su, Zeyu Chen, Daoping Hong, et al.
Chinese Medical Journal|June 30, 2023
Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in a mice model of orthotopic bladder cancerShi Qiu, Yaqi Qiu, Linghui Deng, et al.
Journal for Immunotherapy of Cancer|September 15, 2025
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironmentInbar A Habaz, Xuejin Ou, Nicole I Wang, et al.
Cancer Medicine|September 16, 2024
Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective studyRuopeng Su, Tingxuan Huang, Liangyou Gu, et al.
Current Opinion in Urology|October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panelsBenjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 8